The global graft versus host disease (GvHD) treatment market is set for substantial growth, with an expected valuation of USD 2,713.6 million in 2023. Projected to expand at a compound annual growth rate (CAGR) of 8.2%, the market is anticipated to reach approximately USD 5,960.7 million by 2033.
Graft versus host disease (GvHD) is a common complication following hematopoietic cell transplantation (HCT), and its effective management is crucial for improving patient outcomes. The increasing adoption of corticosteroids and combination therapies is significantly boosting the GvHD treatment market, providing better therapeutic options for patients.
Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1401
In December 2021, the US Food and Drug Administration approved Orencia (abatacept) for the management of GVHD in both adult and pediatric patients. Orencia is used to avoid autoimmune diseases as well as treat them. Through specific attachment to and modification of one of the key costimulation signals sent by these cells, this medicine circumvents the attack of T-cells, which are essential in acute GVHD.
As a result, T-cells are prevented from fully activating, hence preventing acute (GVHD). Surgeons are evaluating several new approaches to prevent (GVHD) in the future.
Customization Available:
https://www.futuremarketinsights.com/customization-available/REP-GB-1401
Key Takeaways:
- The global graft versus host disease (GvHD) treatment market is expected to reach US$5.96 billion by 2033, growing at a CAGR of 8.2%.
- Rising adoption of combination therapies and advancements in allogeneic hematopoietic cell transplant (HCT) are key growth drivers.
- Newer medications like Jakafi and Rezurock offer improved efficacy for chronic GvHD compared to traditional treatments.
Recent improvements in acute graft-versus-host disease (GVHD) severity levels and overall survival rates may be advantageous for allogeneic hematopoietic cell transplant patients; nevertheless, a number of issues still need to be resolved. Furthermore, more recent drug approvals for the prevention and treatment of chronic (GVHD) include Jakafi and Rezurock, which may be more beneficial than earlier ones.
Key Segments Profiled in Market:
By Product:
- Monoclonal antibodies
- mTOR inhibitors
- Tyrosine kinase inhibitors
- Thalidomide
- Etanercept
By Disease:
- Acute Graft Versus Host Disease (aGvHD)
- Chronic Graft Versus Host Disease (cGvHD)
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Obtain In-Depth Market Insights: Purchase Now to Access:
https://www.futuremarketinsights.com/checkout/1401
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
